Glaucoma Surgery Using the ViaLase Laser System
Glaucoma · Glaucoma, Open-Angle
Bottom Line
View on ClinicalTrials.gov: NCT04949802 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- ViaLase Laser (Device)
- Age
- Adult, Older Adult · 35+ yrs
- Sex
- All
- Sponsor
- Vialase, Inc.
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean IOP |
12.7 | — |
| PRIMARY Percent Change From Baseline in Intraocular Pressure |
-38.5 | — |
| SECONDARY Number of Eyes That Achieved >=20% IOP Reduction |
18 | — |
Summary
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary open-angle glaucoma (including pigmentary and pseudoexfoliative glaucoma).
- Glaucomatous visual field defects consistent with optic nerve defects and defined as one or more of the following:
- A cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level on the pattern deviation (PD) plot; or
- Glaucoma hemi-field test "outside normal limits" Note: Visual field reliability indices (i.e., fixation losses, false positives, and false negatives) should all be less than 33%. For subjects with a screening visual acuity of 20/100 or worse, a visual field is not required, and the above criteria do not need to be met.
- Nerve abnormality characteristic of glaucoma as evaluated by clinical ophthalmoscopy defined as one or more of the following:
- Diffuse thinning, focal narrowing or notching of the optic disc rim especially at inferior or superior poles.
- Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at inferior or superior poles.
- Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
- Subject eye is phakic
a. If phakic, then the crystalline lens will not have visually significant cataract that is expected to require cataract surgery within next one year. Cataract will be evaluated by using the AREDS clinical lens grading system (ARLNS). Specifically, crystalline lens must have ARLNS grade of ≤ 1.5 for signs of nuclear opalescence, cortical or posterior subcapsular opacities. Lenticular opacities not characterized by the ARLNS grading system shall also be evaluated (e.g. anterior subcapsular cataracts).
- Mean IOP with medication at screening between 21 mmHg and 35 mmHg, inclusive.
- Iridocorneal angle anatomy defined as follows:
- Trabecular meshwork visible on gonioscopy defined by Shaffer grade ≥ 3.
- Normal anatomy as determined by gonioscopy.
- Light perception or better in the study eye at screening. Note: The non-study eye must not have a Snellen corrected visual acuity (CVA) of worse than 20/200 at screening.
- Age 45 years or older
- Available, willing, with sufficient cognitive awareness to comply with examination procedures and schedules.
- Signed written informed consent.
Exclusion Criteria
- Previous glaucoma surgeries including stent implantation or other laser surgeries on study eye.
- Prior intraocular surgery.
- Glaucoma types as follows:
- Traumatic, uveitic, neovascular, or angle-closure.
- Glaucoma associated with vascular disorders.
- Corneal status as follows:
- Any condition that would preclude safe participation in the study or reliable IOP assessments including active inflammation, edema, keratitis, keratoconjunctivitis, keratouveitis.
- Clinically significant dystrophy such as bullous keratopathy or Fuch's dystrophy.
- Guttata that would preclude safe participation in the study or reliable study assessments.
- Anticipated surgery of any type (including LASIK, LASEK, PRK, cataract, etc.) during the study that may alter IOP measurement.
- Corneal opacities or disorders that would inhibit visualization of the angle (such as severe arcus senilis).
- Central corneal thickness less than 440 microns or greater than 620 microns.
- Choroid status as follows:
- Choroidal detachment
- Effusion
- Choroiditis
- Neovascularization
- Any active choroidopathy.
- Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition including: proliferative diabetic retinopathy, central retinal artery occlusion, central retinal vein occlusion, wet age-related macular degeneration, dry age-related macular degeneration (e. g., presence of numerous large drusen associated with disturbance to or elevation of the retinal pigment epithelium), significant retinal pigment epithelial changes or optic atrophy, pathological myo
Data sourced from ClinicalTrials.gov (NCT04949802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.